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ABSTRACT 
The present research work involve the development of a bilayer tablet of ciprofloxacin hydrochloride using a superdisintegranting agent 
(sodium starch glycolate) for the fast releasing layer and hydrophobic polymers like ethyl cellulose, acrycoat L100 and acrycoat S100 for the 
delayed releasing layer. Ciprofloxacin was used as a model drug. Tablets were prepared by wet granulation method. The prepared bilayer tablets 
were evaluated for angle of repose, bulk density, tapped density, Carr’s index, Hausner’s ratio at the precompression stage and thickness 
variation, weight variation, hardness, friability, drug content, disintegration time,  in vitro drug release study at the post compression stage.. In 
vitro dissolution studies were carried out in a USP 24 apparatus I. In vitro dissolution kinetics followed the Higuchi model via a non-Fickian 
diffusion controlled release mechanism after the initial burst release. FT-IR studies revealed that there was no interaction between the drug and 
polymers. Statistical analysis (ANOVA) showed no significant difference in the cumulative amount of drug release after 15 min, but significant 
difference (p < 0.05) in the amount of drug released after 12 h from optimized formulations was observed. Present research work involves the 
development of a bilayer tablet of ciprofloxacin hydrochloride using a superdisintegrant for the fast releasing layer and hydrophobic polymers 
for the delayed releasing layer. There was the initial burst effect from the formulations to provide the loading dose of the drug, followed by 
sustained release to provide maintenance dose of the drug.  
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INTRODUCTION 
The goal of any drug delivery system is to provide a 
therapeutic amount of the drug to the proper site in the body 
to achieve promptly, and then maintain, the desired drug 
concentration 1. The idealized objective points important to 
the drug delivery, namely, spatial placement and temporal 
delivery of a drug. Spatial placement relates to targeting a 
drug to a specific organ or tissue, while temporal delivery 
refers to the controlling the rate of drug delivery to the 
target tissue. The multilayered tablet concept has been long 
utilized to develop sustained release formulations. Such a 
tablet has a fast releasing layer and may contain bi- or triple 
layers to sustain the drug release. The pharmacokinetic 
advantage relies on the fact that drug release from fast 
releasing granules leads to a sudden rise in the blood 
concentration. However, the blood level is maintained at 
steady state as the drug is released from the sustaining 
granules2. Two layer tablets may be designed for sustained 
release one layer for the immediate release of the drug and 
second layer for extended release thus maintaining a 
prolonged blood level. The weight of each layer can be 
accurately controlled in contrast to putting one drug of a 
combination product in a sugar coating. Bi-layer tablets are 
novel drug delivery systems where combination of two or 
more drugs in a single unit having different release profiles 
which improves patient compliance, prolongs the drug(s) 
action, avoid saw tooth kinetics resulting in effective therapy 
along with better control of plasma drug levels. Bi-layer 
tablets are very common for drugs such as captopril, 
metoprolol, amoxicillin and potassium clavulanate, 
propranolol hydrochloride, bambuterol hydrochloride etc3. 
In the present study ciprofloxacin was used as a model drug. 
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Ciprofloxacin is a broad-spectrum antibiotic belongs to a 
group called fluoroquinolones that is active against both 
Gram-positive and Gram-negative bacteria. It functions by 
inhibiting DNA gyrase, a type II topoisomerase, which is an 
enzyme necessary to separate replicated DNA, thereby 
inhibiting cell division. Ciprofloxacin is rapidly absorbed 
orally, but food delay absorption and first pass effect occurs. 
The most prominent feature of ciprofloxacin is high tissue 
penetrability: concentration in lung, sputum, muscle, bone, 
prostate and phagocytes exceed that in plasma, but CSF and 
aqueous levels are lower. It excreted primarily in urine, both 
by glomerular filtration and tubular secretion, urinary and 
biliary concentration is 10 to 50 fold higher than plasma. 
Hence In comparison with the single sustain layer tablet, a 
double layer containing one immediate release compartment 
and one sustain release layer offers advantages4. The 
objective of the proposed work is to formulate a bi-layer 
tablet which can control the release time after oral 
administration, at a particular site and sustain the release of 
drug. This is especially useful for achieving controlled 
plasma level as well as improving bioavailability. Bi-layer 
drug shall be prepared using wet granulation method or may 
be by dry granulation techniques and study shall be 
employed to finalize the method for the preparation, on the 
basis of several physicochemical parameters. Final dosage 
form will be optimized statistically and shall be evaluated 
and optimized. 
MATERIALS AND METHOD 
Materials: The Ciprofloxacin hydrochloride was a gift 
sample by the Zydus Cadila, Baghekhola, East Sikkim. Acryl 
coat L-100 and Acryl coat S-100 was obtained from Corel 
Pharmachem, Ahmadabad. Ethyl cellulose, Lactose, Starch 
powder, Talcum powder, Microcrystalline cellulose, 
Magnesium stearate were purchased from S.D.Fine – Chem. 
Limited, Mumbai. Sodium starch glycolate, Ethyl alcohol was 
purchased from Lobachemie, Pvt ltd .Mumbai. Tartrazine 
(tatar yellow) was obtained from Burgoyne Burbidge’s& co. 
Mumbai.  
Methodology: 
Formulation of the fast release layer: 
The dose for the fast releasing layer and the delayed 
releasing layer of the tablets were calculated individually5. 
The fast release granules were prepared by wet granulation 
technique by blending the drug uniformly with sodium 
starch glycolate using starch paste (10% m/m) as binder as 
per the formulae given in Table 1. The cohesive mass 
obtained was passed through a 1000μm sieve, dried at 60°C 
for 1 hour. The granules were again passed through a 
1000μmscreen to break up agglomerates. The granules were 
then mixed with talc and magnesium stearate. 
Table 1: Composition of sustained releasing layer 
Sl. no. 
Ingredients 
(quantity/tablets) in mg 
Batch code 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 
Ciprofloxacin 
Hydrochloride 
170 170 170 170 170 170 170 170 170 
2 Ethyl cellulose 85 170 255 … … … … … … 
3 Acrycoat L100 … … … 85 170 255 … … … 
4 Acrycoat S100 … … … … … … 85 170 255 
5 Lactose 190 105 20 190 105 20 190 105 20 
6 Starch paste10% 40 40 40 40 40 40 40 40 40 
7 Talc 6 6 6 6 6 6 6 6 6 
8 Magnesium stearate 4 4 4 4 4 4 4 4 4 
 
Formulation of the sustained release layer: 
The granules for sustaining layer of the tablets were also 
formulated by the wet granulation technique by mixing the 
drug individually with the polymer (acrycoat S100, ethyl 
cellulose and acrycoat L100) uniformly followed by lactose6. 
Starch paste (10% m/m) was incorporated as binder in the 
formulations (Table 2). The sustaining granules were also 
subjected to similar processing steps as the fast releasing 
granules.
 
Table 2: Composition of fast releasing layer 
Sl.no. Ingredients (quantity/tablets) in mg Quantity for a single tablet in mg 
1. Ciprofloxacin Hydrochloride 80 
2. Sodium starch glycolate 8 
4. Starch paste (10%) 25 
5. Talcum powder 2 
6. Magnesium stearate 1 
 
Preformulation Studies 
The preformulation studies like angle of repose, bulk density, 
tapped density3, 7. Compressibility or Carr’s index drug 
excipients compatibility studies, Hausner’s ratio8 were 
evaluated which was shown in table 3. 
Compression of Bilayer tablets:  
The granules for the sustained release layer was compressed 
lightly using a single punch-tableting machine (Rimek Mini 
Press 1,Shakti Engineering Ltd, India) equipped with 6.5mm 
round, flat and plain punches. Over this compressed layer, 
the required quantity of granules for the fast release layer 
were placed and compressed again to obtain the hardness of 
the resultant tablets in the range of 5–7 kg cm–2. 
Physical tests for Bilayer tablets 9-11 
Standard physical tests for the bilayer matrix tablets were 
performed and average values were calculated. 20 tablets 
were individually weighed and then their average weight 
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was calculated. The average weight was compared with the 
individual tablet weights and the weight variation was 
calculated. The hardness of the prepared tablets was 
determined by using Monsanto tablet hardness tester (Royal 
Scientific Pvt. Ltd, Chennai). Twenty tablets were weighted 
again, introduced into the plastic chamber of the friability 
apparatus (Electrolab, Mumbai), The apparatus was 
operated for 4 minutes at 25 rpm. These tablets were then 
again weighed and percentage loss in weight was calculated.  
Determination of drug content in tablets: 
Three tablets from each batch were selected randomly and 
transferred to 100ml volumetric flasks which were filled up 
with 0.1 (N) hydrochloric acid of pH 1.2 kept it for 24 hours, 
then took 1ml from each of volumetric flask and was 
transferred to the test tubes. Samples were then filtered, 
suitably diluted and analyzed spectrophotometrically at a 
wavelength of 277.5nm which is given in table 4. 
Determination of in-vitro dissolution study: 
Dissolution study was carried out in USP –II type dissolution 
apparatus (paddle type) in TDT 08L model (Electrolab, 
Kolkata). Dissolution study was performed at 50 rpm in 
900ml of simulated gastric fluid of pH 1.2 for the first 2 
hours and followed by simulated intestinal fluid of pH 6.8 
phosphate buffer for the remaining hours. The temperature 
was maintained at 37 ± 0.2oC. 5ml of sample was withdrawn 
at a predetermined interval and the volume of dissolution 
medium was maintained by adding same volume of 
dissolution medium each time. Then the sample was filtered 
through Whatmann filter paper. The absorbance of 
withdrawn sample was measured spectrophotometrically at 
277.5 nm after suitable dilution and the corresponding 
concentration was determined from the respective 
calibration curve. 
Statistical Analysis (One-way Analysis of Variance or 
ANOVA) 12: 
In-vitro drug release data from the optimized bilayer tablet 
formulations were subjected to the analysis of variance 
(ANOVA) at two different time intervals, likely at the first 15 
minutes and at the 10th hour using Graph pad Instat software 
version 3.10. For in-vitro dissolution testing at the first 15 
minute, each formulation was subjected three times and the 
percentage cumulative drug release was calculated shown in 
table 5. For in-vitro dissolution testing at the 10th hour, each 
formulation was subjected three times and the percentage 
cumulative drug release was calculated shown in table 8. 
Then the data of three optimized formulations were 
subjected to one way ANOVA analysis using Tukey testing-all 
column comparison test which was shown in table 9. 
Drug-polymer compatibility study using FT-IR 
spectrophotometer 11: 
FT-IR study was carried out to identify any possible drug-
polymer interaction. The peaks of pure drug and pure 
individual polymers were compared to the mixtures of the 
same and any significant shifting of the band was noted as 
the sign of interaction which is shown in Figure. 
RESULT AND DISCUSSSION 
In this preformulation study, prepared granules were 
evaluated for various physical properties shown in table 3. 
The bulk densities for the granules of various formulations 
ranged between 0.502±0.654 gm/ml and 0.598±0.061 
gm/ml, as determined by the tapped density method. This 
value of bulk density indicates of good packing character. 
The compressibility index (Carr’s index) for all the 
formulations was found to be almost below 17%, indicating 
desirable flow properties. The flow properties of the 
granules were further analyzed by determining the angle of 
repose for all granules; it ranged between 19.66º±0.538º 
and 26.75º±0.735º. The value indicates good flow 
properties of granules with ethyl cellulose, acrycoatL100 and 
acrycoat S100 as matrix material. Hausner’s ratio also 
calculated for the granules flow property determination and 
seems to be within the suitable range i.e.; below 2.5. The 
results of the preformulation study of drug and the 
physicochemical properties of the prepared tablets are given 
in table 4 accordingly. 
  
Table 3: Results of the evaluations conducted at preformulation stages 
Batch 
no. 
Angle of repose 
(º) 
Bulk density        
(gm/ml) 
Tapped density 
(gm/ml) 
Carr’s index 
% 
Hausner’s Ratio 
F1 
 
25.33±0.363 0.551±0.0821  0.665±0.894 14.01±0.509 1.206 
F2 
 
24.23±0.259  0.521±0.0534 0.581±0.941 13.014±0.331   1.115 
F3 
 
22.12±0.244 0.582±0.758 0.641±0.290 11.34±0.162 1.1013 
F4 
 
26.75±0.735 0.574±0.3115  0.673±0.533 17.31±0.649 1.1724 
F5 
 
24.46±0.338 0.511±0.341 0.593±0.734 14.05±0.947   1.1604 
F6 
 
21.39±0.567 0.502±0.654 0.598±0.318  14.349±0.845 1.1912 
F7 
 
25.08±0.198 0.598±0.061  0.657±0.431 16.14±0.068   1.0986 
F8        22.7±0.933 0.524±0.141 0.593±0.334 13.31±0.649 1.1316 
F9 19.66±0.538 0.555±0.304 0.598±0.018 11.5±0.947 1.0774 
 
During preformulation study, FT-IR (Fourier Transform 
Infrared) spectrophotometer was used to determine the 
compatibility in between drug and polymers and with 
excipient. Study was carried out for the pure drug 
(Ciprofloxacin hydrochloride) alone and in combination with 
polymers (Ethyl cellulose, Acrycoat S100 and Acrycoat L100) 
and excipient (Sodium starch glycolate) under study shown 
in figure 1 to figure 4. Major frequencies of functional groups 
of pure drug remained unchanged in presence of polymer. 
Hence, it seems that there is no major interaction between 
the drug and the polymers used in the study. 
 
 
Kar et al                                                                                                                          Journal of Drug Delivery & Therapeutics. 2019; 9(1):46-53 
ISSN: 2250-1177                                                                                  [49]                                                                                 CODEN (USA): JDDTAO 
Table 4: Results of studies conducted for physico-chemical characteristics of the prepared tablet 
Formulation Thickness 
variation (cm) 
Weight 
variation 
Hardness 
(Kg/cm2) 
Friability 
(%) 
Disintegration 
Time (hrs) 
Drug content 
(%) 
F1 0.41±0.03 609 ±3.8 5.5±0.8 0.9 5.05±0.065 101±1.34 
F2 0.40±0.02 611±2.92 6.1±0.5 0.88 7.21±0.031 98±2.31 
F3 0.39±0.02 608±4.4 6.0±0.3 0.78 7.35±0.016 99±3.56 
F4 0.41±0.06 609±2.21 6.3±.0.7 0.91 5.50±0.07 100±2.21 
F5 0.39±0.04 610±3.78 5.4±0.8 0.814 6.05±0.051 102±1.45 
F6 0.40±0.05 608±4.89 5.2±0.4 0.71 6.40±0.042 99±3.12 
F7 0.41±0.04 612±3.76 5.6±0.2 0.962 5.49±0.071 102±2.65 
F8 0.41±0.03 608±3.18 5.8±0.7 0.76 6.40±0.049 101±2.12 
F9 0.40±0.02 611±4.98 6.0±0.5 0.67 7.140±0.044 98±2.32 
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CIPROFLOXACIN HCL+E.C.  
Figure 1: FTIR-Spectra of Ciprofloxacin hydrochloride with Ethyl cellulose 
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Figure 2: FTIR-Spectra of Ciprofloxacin hydrochloride with Acrycoat S100 
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Figure 3: FTIR-Spectra of Ciprofloxacin hydrochloride with Acrycoat L100 
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CIPROFLOXACIN HCL+SODIUM STERCH GLYCOLATE  
Figure 4: FTIR-Spectra of Ciprofloxacin hydrochloride with Sodium starch glycolate 
 
The release of ciprofloxacin hydrochloride from the 
prepared formulations was analyzed by different release 
kinetics model as shown in figure 5 to figure 9. Simple visual 
observation of the plot shows an initial burst effect.  From all 
the formulations, near 30% of the ciprofloxacin 
hydrochloride was released within the first 15 minutes of the 
dissolution study. This initial high amount of ciprofloxacin 
hydrochloride release can be attributed to the immediate 
release layer of the formulations.  
In the formulations F1, F2, F3, as the proportion of the ethyl 
cellulose increases, the release rate of the drug decreases. 
Formulation F1 could not sustain the release beyond 7 hours 
where drug and EC was in a ratio of 1:0.5, whereas other 
formulations like F2 and F3 where drug and EC ratios were 
1:1 and 1:1.5 respectively have shown the desired release 
profile over the test period of 10 hours. Therefore, 
formulation F2 was selected as the optimized formulation 
keeping in view that this formulation involves minimum 
amount of ethyl cellulose required to sustain the release of 
the contained drug for a period of 10 hours. It has been 
evidence that the formulation F2 was obeying the Higuchi 
release pattern with the R2value of 0.9539). For further 
confirmation of the drug release mechanism, results of the 
in-vitro dissolution data were fitted to the Korsmeyer-
Peppas kinetics model. The value of the release exponent (n) 
for the optimized formulation F2 was found to be 0.3756 
indicating the release governed by Fickian diffusion. 
Similarly, formulations containing acrycoat L100 and 
acrycoat S100 were also examined to check their ability to 
sustain the drug release pattern. Formulations F4 and 
F5,where drug and acrycoat L100 was in a ratio of 1:0.5 and 
1:1 respectively and formulations F7 and F8, where drug and 
acrycoat S100 ratio was 1:0.5 and 1:1 respectively were 
found to release maximum of the contained drug well before 
12 hours i,e; within 10 hours. However, the formulation F6 
and F9 where the drug was combined with acrycoat L100 
and acrycoat S100 in a ratio of 1:1.5 each was found to 
sustain the release of the drug well above 12 hours since 
minimum drug release occurred within 10 hours from both 
the formulations. Hence, formulation F6 and F9 were 
selected as the optimized formulations. It has been evidence 
that the drug release from these formulations was obeying 
the Higuchi release pattern with the R2value of 0.9545and 
0.9510 respectively. The Korsmeyer-Peppas release (Figure 
5) exponent (n) for the formulation F6 and F9 was found to 
be 0.394 and 0.397, indicating release governed by the 
Fickian diffusion. 
The shape factor ‘b’ as a Weibull function was determined for 
each of the formulations (Figure 6). Complex release 
mechanism i.e., the rate of release increases up to the 
inflection point and there after declines is seen if the b value 
is more than 1. It has been found that for all the 
formulations, b values were ranging in between 0.39 to 0.69 
which clearly indicate that diffusion in fractional or disorder 
substrate and different from the percolation cluster. Almost 
all the formulations prepared with ethyl cellulose, acrycoat 
L100 and acrycoat S100 have found to be predominantly 
obeying the Higuchi kinetics, Zero order kinetics and Fickian 
diffusion in their drug release behavior after the initial burst 
release.
  
 
Figure 5: Zero order release profile of all formulations 
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Figure 6: Higuchi release profile of all formulations 
 
 
Figure 7: First order release profile of all formulations 
 
 
Figure 8: Korsmeyer-Peppas release profile of all formulations 
 
Figure 9: Weibull kinetics release profile of all formulations 
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Statistical analysis (using one-way ANOVA analysis) has 
been showed that no significant difference occurred in the 
amount of drug release after the first 15 minutes from the 
optimized formulations shown in table 5, since the p value is 
0.8633.So it is evident that the initial burst of the fast release 
layer takes place from almost all the formulations 
irrespective of the polymer contents in them. Statistical 
analysis (using one-way ANOVA analysis) has shown that 
extremely significant difference occurred in the amount of 
drug release after the 10th hours from the optimized 
formulations shown in table 8, as the p value is < 0.0001. So 
it is evident that the incorporation of different polymers in 
different ratios for sustaining the release of the contained 
drug resulted in the variation in the observations. 
 
Table 5: Summary of data at the first 15 mints (optimized formulations F2, F6 and F9). 
Group Minimum Maximum 95% Confidence Interval 
From To 
Column A 28.099 28.780 27.533 29.263 
Column B 27.999 28.824 27.200 29.423 
Column C 27.4076 28.678 27.188 29.245 
 
Table 6: Intermediate calculations of drug release at 15 minute using one-way ANOVA 
Source of variation Degrees of freedom Sum of squares Mean square 
Treatments (between columns) 2 0.04949 0.02475 
Residuals (within columns) 6 0.9859 0.1643 
Total 8 1.035  
F= 0.1506 = (MStreatment/ MSresidual) 
 
Group Number of 
points 
Standard mean Standard Error of Deviation Mean Median 
Column A 3 28.398 0.3482 0.2010 28.314 
Column B 3 28.312 0.4475 0.2584 28.112 
Column C 3 28.216 0.4140 0.2390 28.091 
(Values are given in mean ± SD, n=3) 
Table 7: Summary of data at 10th hour (optimized formulations F2, F6 and F9). 
Group Minimum Maximum 95% Confidence Interval 
From To 
Column A 87.989 88.879 87.317 89.531 
Column B 83.981 84.743 83.342 85.283 
Column C 84.904 85.893 84.203 86.733 
 
Table 8: Intermediate calculations of drug release at 10 hour using one way ANOVA. 
Source of variation Degrees of freedom Sum of squares Mean square 
Treatments (between columns) 2 26.978 13.489 
Residuals (within columns) 6 1.221 0.2034 
Total 8 28.199  
F= 66.312 = (MStreatment/ MSresidual) 
 
Group Number of 
points 
Standard mean Standard Error 
of Deviation 
Mean Median 
Column A 3 88.424 0.4454 0.2572 88.404 
Column B 3 84.312 0.3906 0.2255 84.213 
Column C 3 85.468 0.5092 0.2940 85.608 
(Values are given in mean ± SD, n=3) 
Table 9: Tukey-Kramer multiple comparisons test. 
Comparison Mean difference q P value 
Column A vs. Column B 4.112 15.790 *** P<0.001 
Column A vs. Column C 15.790 11.351 *** P<0.001 
Column B vs. Column C -1.156 4.438 *   P<0.05 
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CONCLUSION 
 The objective of the proposed work was to develop a Novel 
Drug Delivery System (NDDS) in the form of orally 
administered fast and slow releasing bilayer tablet 
containing Ciprofloxacin Hydrochloride. Polymers like ethyl 
cellulose, acrycoat L100 and acrycoat S100 in different ratios 
have been examined for matrix forming properties to 
regulate the release of contained drug. Proposed work was 
aimed at the delivery of the drug throughout a time span of 
up to 10 hours. Detailed investigation on the present topic 
has certainly added a newer dimension towards the 
controlled release of ciprofloxacin hydrochloride. 
Present research work involve the development of a bilayer 
tablet of ciprofloxacin hydrochloride using a 
superdisintegranting agent (sodium starch glycolate) for the 
fast releasing layer and hydrophobic polymers like ethyl 
cellulose, acrycoat L100 and acrycoat S100 for the delayed 
releasing layer. There was the initial burst effect from the 
formulations to provide the loading dose of the drug, 
followed by sustained release to provide maintenance dose 
of the drug. Ciprofloxacin hydrochloride bilayer tablets were 
found promising and as potential alternative to the 
conventional dosage form of the drug. 
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